After the first part of this year’s Generics Bulletin Top 50 showed upheaval among the top 10 leading off-patent companies and the second part demonstrated movement among the mid-table players (see sidebar), this third and final section of the ranking sees a handful of new entrants making their way into the bottom of the chart, while others exit altogether.
The Generics Bulletin Top 50, Part Three: Newcomers Climb Into Bottom Table
As Some Firms Disappear From The Ranking This Year, Others Fill Their Places
In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.
More from Company Rankings
• By
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
• By
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
• By
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
• By
A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.